Breaking News

Jabil Acquires Pii

Enhances its existing pharmaceutical solutions, enabling comprehensive support for customers in drug development, clinical trials, and product commercialization at scale.

Jabil Inc., a provider of engineering, manufacturing, and supply chain solutions, has acquired Pharmaceutics International Inc. (Pii), a contract development and manufacturing organization (CDMO) specializing in early-stage, clinical, and commercial volume aseptic filling, lyophilization, and oral solid dose manufacturing.

“As the pace of healthcare innovation accelerates, pharmaceutical companies need partners who can help them scale rapidly with a focus on quality and safety. Jabil and Pii’s combined capabilities can provide end-to-end support for pharmaceutical customers, offering one safe, trusted pair of hands to simplify their entire supply chain,” said Mike Mahaz, SVP, Global Business Units, Healthcare, at Jabil.

Benefits of the Acquisition

This acquisition will significantly enhance Jabil’s existing Pharmaceutical Solutions offering, which includes the development and commercial production of auto-injectors, pen injectors, inhalers, and on-body pumps. With the addition of Pii’s scientific insights, depth of product knowledge, and capabilities across aseptic filling, lyophilization, and oral solid dose manufacturing, Jabil can meet the clinical and commercial drug manufacturing demands of healthcare customers.

“With our shared commitment to creating the best solutions possible for patients around the world, we believe the addition of Pii’s capabilities, supported by over 300 team members, is a perfect fit for Jabil and our customers,” said James O’Gorman, Vice President, Pharmaceutical Solutions, at Jabil. “The convergence of Jabil’s and Pii’s complementary capabilities will bolster Jabil’s customer offering and support business growth potential as we enter the CDMO market.”

Founded in 1994, Pii’s footprint has grown to over 360,000 square feet across four sites on a single campus in Hunt Valley, Maryland. Pii’s Good Manufacturing Practice (GMP) facilities contain over 70 manufacturing rooms, including containment suites for handling high potency compounds and hormones, dedicated manufacturing suites for oral products (e.g., soft gels), an aseptic facility for injectables (e.g., vials, syringes, and cartridges), a formulation development center, and analytical and microbiology laboratories. This expertise will add a comprehensive portfolio of pharmaceutical development and manufacturing services to Jabil’s current healthcare solutions.

By joining Jabil, Pii gains access to an expanded global infrastructure, cutting-edge automation, and enhanced supply chain efficiencies, enabling even greater responsiveness and innovation for its pharmaceutical partners.

“This acquisition marks an exciting new chapter for Pii. We look forward to leveraging Jabil’s extensive expertise to accelerate our mission of delivering best-in-class drug development and manufacturing solutions to our customers and ultimately the patients we serve,” added John Fowler, President and CEO at Pii.

More Pharmaceutical Industry Acquisitions

Read Contract Pharma’s frequently updated Pharmaceutical Industry Mergers & Acquisitions Roundup.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters